DeutschNewstral
Article
Mmarketwatch.com on 2020-04-23 13:45
AstraZeneca to test diabetes drug in severely ill COVID-19 patients
Related news
- MAstraZeneca to test blood-cancer drug for severely ill COVID-19 patientsmarketwatch.com
- FAstraZeneca diabetes drug cuts death ratesft.com
- FArthritis drug offers hope for severely ill Covid patientsft.com
- MU.K. trial sparks interest in dexamethasone’s potential as a treatment for severely ill COVID-19 patientsmarketwatch.com
- MPhysicians prescribe steroid used to treat severely ill COVID-19 patients to Trumpmarketwatch.com
AstraZeneca gets an additional FDA approval for its diabetes drugbizjournals.com
AstraZeneca diabetes drug combination faces approval delay after FDA rebufftimesofmalta.com- FAstraZeneca chief says NHS drug approval process hurts patientsft.com
AstraZeneca PLC: AstraZeneca beats estimates with strong cancer and diabetes drug salesFinancial Times
AstraZeneca launches trial to assess whether diabetes medicine can be repurposed for Covid-19 patientscambridgeindependent.co.uk
Severely ill patients in Maine now receiving new drug to fight COVID-19pressherald.com
Health Canada approves drug to treat COVID-19 in immunocompromised patients, AstraZeneca saysCBC- HAstraZeneca Blood Cancer Drug Shows Signs of Helping COVID-19 Patientshamodia.com
- AstraZeneca begins clinical trial of blood cancer drug Calquence for Covid-19 patientscambridgeindependent.co.uk
- FAstraZeneca diabetes drug cuts complicationsft.com
- FAstraZeneca cancer drug breakthroughft.com
Number of severely ill COVID-19 patients surge in JapanThe Japan Times
COVID-19 blood plasma therapy ineffective in severely ill patientsnewatlas.com
Older blood as effective as new for severely ill patientsThe Globe and Mail- MU.K. approves dexamethasone for some severely ill coronavirus patientsmarketwatch.com